Previous Close | 0.0800 |
Open | 0.0800 |
Bid | 0.0800 x 0 |
Ask | 0.0999 x 0 |
Day's Range | 0.0800 - 0.0800 |
52 Week Range | 0.0540 - 0.2610 |
Volume | |
Avg. Volume | 8,669 |
Market Cap | 4.408M |
Beta (5Y Monthly) | 1.97 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announced today that it intends to complete a small non-brokered private placement financing (the "Offering") of up to 3,000,000 units of the Company, (each a "Unit") at a price of $0.10 per each Unit for a gross proceeds of up to $300,000.00. ...
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive characterization of tissue with an application in breast imaging, announces that further to its January 8th disclosure, it has received a response from the U.S. FDA. The FDA's mammogram and ultrasound
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive characterization of tissue with an application in breast imaging, provides an update on its regulatory status with the U.S. Food and Drug Administration ("FDA") and operational activities. FDA Regulato